These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 11803062)

  • 1. Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines.
    Ragupathi G; Cappello S; Yi SS; Canter D; Spassova M; Bornmann WG; Danishefsky SJ; Livingston PO
    Vaccine; 2002 Jan; 20(7-8):1030-8. PubMed ID: 11803062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers.
    Ragupathi G; Koide F; Sathyan N; Kagan E; Spassova M; Bornmann W; Gregor P; Reis CA; Clausen H; Danishefsky SJ; Livingston PO
    Cancer Immunol Immunother; 2003 Oct; 52(10):608-16. PubMed ID: 12811527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines.
    Kim SK; Ragupathi G; Musselli C; Choi SJ; Park YS; Livingston PO
    Vaccine; 1999 Nov; 18(7-8):597-603. PubMed ID: 10547417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Keyhole limpet hemocyanin conjugate vaccines against cancer: the Memorial Sloan Kettering experience.
    Musselli C; Livingston PO; Ragupathi G
    J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R20-6. PubMed ID: 11768620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates.
    Kim SK; Ragupathi G; Cappello S; Kagan E; Livingston PO
    Vaccine; 2000 Oct; 19(4-5):530-7. PubMed ID: 11027818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Constructing an adenocarcinoma vaccine: immunization of mice with synthetic KH-1 nonasaccharide stimulates anti-KH-1 and anti-Le(y) antibodies.
    Ragupathi G; Deshpande PP; Coltart DM; Kim HM; Williams LJ; Danishefsky SJ; Livingston PO
    Int J Cancer; 2002 May; 99(2):207-12. PubMed ID: 11979435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21.
    Ragupathi G; Meyers M; Adluri S; Howard L; Musselli C; Livingston PO
    Int J Cancer; 2000 Mar; 85(5):659-66. PubMed ID: 10699946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.
    Slovin SF; Ragupathi G; Musselli C; Fernandez C; Diani M; Verbel D; Danishefsky S; Livingston P; Scher HI
    Cancer Immunol Immunother; 2005 Jul; 54(7):694-702. PubMed ID: 15726361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of sialyl Lewis(a) (sLe (a), CA19-9) and construction of an immunogenic sLe(a) vaccine.
    Ragupathi G; Damani P; Srivastava G; Srivastava O; Sucheck SJ; Ichikawa Y; Livingston PO
    Cancer Immunol Immunother; 2009 Sep; 58(9):1397-405. PubMed ID: 19190907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.
    Ragupathi G; Livingston PO; Hood C; Gathuru J; Krown SE; Chapman PB; Wolchok JD; Williams LJ; Oldfield RC; Hwu WJ
    Clin Cancer Res; 2003 Nov; 9(14):5214-20. PubMed ID: 14614001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of DHBcAg as a potent carrier protein comparable to KLH for augmenting MUC1 antigenicity.
    Gathuru JK; Koide F; Ragupathi G; Adams JL; Kerns RT; Coleman TP; Livingston PO
    Vaccine; 2005 Sep; 23(39):4727-33. PubMed ID: 15978705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl)cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells.
    Ragupathi G; Howard L; Cappello S; Koganty RR; Qiu D; Longenecker BM; Reddish MA; Lloyd KO; Livingston PO
    Cancer Immunol Immunother; 1999 Apr; 48(1):1-8. PubMed ID: 10235483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines.
    Livingston PO
    Immunol Rev; 1995 Jun; 145():147-66. PubMed ID: 7590824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies.
    Yao TJ; Meyers M; Livingston PO; Houghton AN; Chapman PB
    Clin Cancer Res; 1999 Jan; 5(1):77-81. PubMed ID: 9918205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of antigen constructs and carrier molecules for augmenting the immunogenicity of the monosaccharide epithelial cancer antigen Tn.
    Kagan E; Ragupathi G; Yi SS; Reis CA; Gildersleeve J; Kahne D; Clausen H; Danishefsky SJ; Livingston PO
    Cancer Immunol Immunother; 2005 May; 54(5):424-30. PubMed ID: 15625606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci.
    Krug LM; Ragupathi G; Hood C; George C; Hong F; Shen R; Abrey L; Jennings HJ; Kris MG; Livingston PO
    Cancer Immunol Immunother; 2012 Jan; 61(1):9-18. PubMed ID: 21811785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward optimized carbohydrate-based anticancer vaccines: epitope clustering, carrier structure, and adjuvant all influence antibody responses to Lewis(y) conjugates in mice.
    Kudryashov V; Glunz PW; Williams LJ; Hintermann S; Danishefsky SJ; Lloyd KO
    Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3264-9. PubMed ID: 11248067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines.
    Helling F; Shang A; Calves M; Zhang S; Ren S; Yu RK; Oettgen HF; Livingston PO
    Cancer Res; 1994 Jan; 54(1):197-203. PubMed ID: 8261439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients.
    Adluri S; Helling F; Ogata S; Zhang S; Itzkowitz SH; Lloyd KO; Livingston PO
    Cancer Immunol Immunother; 1995 Sep; 41(3):185-92. PubMed ID: 7553688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial.
    Sabbatini PJ; Kudryashov V; Ragupathi G; Danishefsky SJ; Livingston PO; Bornmann W; Spassova M; Zatorski A; Spriggs D; Aghajanian C; Soignet S; Peyton M; O'Flaherty C; Curtin J; Lloyd KO
    Int J Cancer; 2000 Jul; 87(1):79-85. PubMed ID: 10861456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.